Myriad offers an array of genetic tests, prognostic tests, and personalized medicine tests to healthcare providers to help them assess a patient’s increased cancer risk, disease aggressiveness, optimize efficacy of chemotherapy and identify patients most suitable for therapy.
MyChoice® CDx Plus is the most comprehensive tumor test that determines HRD status in patients with ovarian cancer, fallopian tube and primary peritoneal cancer. This CE marked test helps to identify ovarian cancer patients with a Homologous Recombination Deficiency who might be considered for treatment with PARPi therapy.
MyChoice® CDx is the first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status.
BRACAnalysis CDx® is an FDA-approved laboratory developed test for BRCA1 and BRCA2 intended to inform patient management related to the PARP inhibitors, Lynparza® (olaparib) and Zejula® (niraparib).
Myriad MyRisk™ Hereditary Cancer is a multi-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on 11 primary cancer sites.
Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.
EndoPredict® is the only test that answers the following three important clinical questions…
… to optimize treatment for breast cancer patients.
Please try changing the search criteria, or reset filters